Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.04
(-5.99%)
CAD 2.04
(-5.99%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 49.89 Million USD | -28.8% |
| 2022 | 70.08 Million USD | 27.74% |
| 2021 | 54.86 Million USD | 22.26% |
| 2020 | 44.87 Million USD | 15.62% |
| 2019 | 38.81 Million CAD | 130.05% |
| 2018 | 16.87 Million CAD | 399.05% |
| 2017 | 3.38 Million CAD | 4.26% |
| 2016 | 3.24 Million CAD | 7.61% |
| 2015 | 3.01 Million CAD | 6.48% |
| 2014 | 2.82 Million CAD | 24325.31% |
| 2013 | 11.58 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 46.83 Million USD | -6.13% |
| 2023 Q4 | 49.89 Million USD | -4.57% |
| 2023 Q1 | 72.92 Million USD | 4.05% |
| 2023 Q2 | 72.08 Million USD | -1.15% |
| 2023 Q3 | 52.28 Million USD | -27.47% |
| 2023 FY | 49.89 Million USD | -28.8% |
| 2022 Q1 | 57.5 Million USD | 4.82% |
| 2022 Q4 | 70.08 Million USD | 6.73% |
| 2022 Q3 | 65.66 Million USD | 8.41% |
| 2022 FY | 70.08 Million USD | 27.74% |
| 2022 Q2 | 60.56 Million USD | 5.32% |
| 2021 Q2 | 47.39 Million USD | -8.34% |
| 2021 Q4 | 54.86 Million USD | 3.52% |
| 2021 Q3 | 52.99 Million USD | 11.83% |
| 2021 Q1 | 51.7 Million USD | 15.23% |
| 2021 FY | 54.86 Million USD | 22.26% |
| 2020 Q2 | 42.1 Million CAD | 5.44% |
| 2020 FY | 44.87 Million USD | 15.62% |
| 2020 Q3 | 50.56 Million CAD | 20.11% |
| 2020 Q4 | 44.87 Million USD | -11.27% |
| 2020 Q1 | 39.93 Million CAD | 2.89% |
| 2019 Q4 | 38.81 Million CAD | 92.36% |
| 2019 FY | 38.81 Million CAD | 130.05% |
| 2019 Q3 | 20.17 Million CAD | 5.08% |
| 2019 Q1 | 18.72 Million CAD | 10.97% |
| 2019 Q2 | 19.2 Million CAD | 2.56% |
| 2018 Q1 | 3.4 Million CAD | 0.72% |
| 2018 Q4 | 16.87 Million CAD | 2.92% |
| 2018 FY | 16.87 Million CAD | 399.05% |
| 2018 Q2 | 3.57 Million CAD | 5.02% |
| 2018 Q3 | 16.39 Million CAD | 358.42% |
| 2017 FY | 3.38 Million CAD | 4.26% |
| 2017 Q1 | 3.41 Million CAD | 5.36% |
| 2017 Q4 | 3.38 Million CAD | -9.61% |
| 2017 Q3 | 3.73 Million CAD | 1.54% |
| 2017 Q2 | 3.68 Million CAD | 7.82% |
| 2016 Q3 | 3.13 Million CAD | 0.34% |
| 2016 FY | 3.24 Million CAD | 7.61% |
| 2016 Q2 | 3.12 Million CAD | 0.87% |
| 2016 Q4 | 3.24 Million CAD | 3.48% |
| 2016 Q1 | 3.09 Million CAD | 2.74% |
| 2015 Q2 | 2.73 Million CAD | -6.46% |
| 2015 Q1 | 2.92 Million CAD | 3.33% |
| 2015 FY | 3.01 Million CAD | 6.48% |
| 2015 Q4 | 3.01 Million CAD | 12.59% |
| 2015 Q3 | 2.67 Million CAD | -2.15% |
| 2014 Q3 | 4912.74 CAD | -18.01% |
| 2014 Q2 | 5991.87 CAD | -23.89% |
| 2014 FY | 2.82 Million CAD | 24325.31% |
| 2014 Q1 | 7872.41 CAD | 0.0% |
| 2014 Q4 | 2.82 Million CAD | 57498.69% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | 543.91 Thousand CAD | 0.0% |
| 2013 FY | 11.58 Thousand CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | -100.0% |
| 2012 Q3 | 1.87 Million CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Aurora Cannabis Inc. | 104.79 Million CAD | 52.385% |
| Avicanna Inc. | 1.8 Million CAD | -2666.778% |
| Avant Brands Inc. | 18.7 Million CAD | -166.795% |
| Cardiol Therapeutics Inc. | 158.53 Thousand CAD | -31373.772% |
| Crescita Therapeutics Inc. | 1.25 Million CAD | -3878.947% |
| Knight Therapeutics Inc. | 69.09 Million CAD | 27.782% |
| MediPharm Labs Corp. | 2.29 Million CAD | -2074.118% |
| OrganiGram Holdings Inc. | 155 Thousand CAD | -32090.968% |
| Canopy Growth Corporation | 683.17 Million CAD | 92.696% |
| Willow Biosciences Inc. | 2.15 Million CAD | -2214.286% |
| Auxly Cannabis Group Inc. | 159.04 Million CAD | 68.628% |